Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study

Published:2022-12 Issue:8 Volume:23 Page:720-730
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Ahn Myung J.,Kim Hye R.,Yang James C.H.,Han Ji-Yu,Li Jacky Yu-Chung.,Hochmair Maximilian J.,Chang Gee-Chen,Delmonte Angelo,Lee Ki H.,Campelo Rosario G.,Gridelli Cesare,Spira Alexander I.,Califano Raffaele,Griesinger Frank,Ghosh Sharmistha,Felip Enriqueta,Kim Dong-Wan,Liu Yuyin,Zhang Pingkuan,Popat Sanjay,Camidge D. Ross

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference24 articles.

1. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer;Gainor;Clin Cancer Res,2013

2. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer;Koivunen;Clin Cancer Res,2008

3. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS;Wong;Cancer,2009

4. Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer;Nishio;Cancer Res Treat,2018

5. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?;Expert Opinion on Therapeutic Targets;2024-08-19

2. Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons;Clinical Lung Cancer;2024-08

3. Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials;Cancers;2024-07-04

4. Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK+ non‐small cell lung cancer using South Korean claims data (K‐AREAL);Cancer Medicine;2024-07

5. Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE);Journal of Thoracic Oncology;2024-06